EazeBio makes biomarker testing more accessible through rapid, convenient testing and AI-powered insights. Track your health over time and make more informed decisions.
Recognized by the Digital Health Hub Foundation at HLTH 2026 alongside our accelerated clinical AI computing membership and registered U.S. FDA diagnostic device portfolio.
Healthcare & Life Sciences program member for accelerated clinical AI inference.
Seven active Class I, 510(k)-exempt diagnostic device listings registered with the U.S. FDA.
More Than a Test. A Better Understanding of Your Health.
EazeBio combines rapid biomarker testing with digital health insights to help people understand their biology and track meaningful changes over time.
See how EazeBio puts advanced biomarker testing within reach. Collect your sample, scan the code, and access detailed health data and wellness recommendations directly on your phone.
Convenient biomarker testing and personalized insights to help you understand your health over time.
Rapid biomarker testing and structured results designed to support professional workflows and informed care.
Use a simple test kit to collect a small sample.
Use your smartphone with our compatible reader.
View your biomarker results through an easy-to-understand app.
Follow your health trends and receive personalized insights.
31 Oct 2025
A hybrid DNA aptamer and antibody-Europium nanoparticle (Eu NP) fluorescent sandwich lateral flow (LF) assay for Tau441 is described which works well in human serum with an apparent visible detection limit for Tau 441 of ~ 10 pg/ml or 1 pg of Tau protein. The same LF assay appears to detect phosphorylated threonine 217 Tau 441 (phospho Thr-217 Tau) consistently to an even lower level of 1 pg/ml or 100 fg of total phosphorylated Tau protein in human serum. The aptamer was designed in silico on the Xelari computational platform to target an epitope centered around alanine 390 distal from the threonine 217 phosphorylation site, thus the monoclonal antibody must account for the possibly greater affinity for the phosphorylated protein on the other side of the target molecule.
27 June 2026
EazeBio's cortisol assay has been published in the Journal of Fluorescence (2026) — the first lateral-flow sandwich fluorescence assay for cortisol, enabled by de novo–designed proteins from the lab of Nobel laureate David Baker. The assay delivers lab-grade cortisol measurement from saliva or serum in about 15 minutes with a handheld reader — no laboratory, no cold chain. It's a milestone in our mission to make meaningful biology measurable at home, over time, and simple to act on.
31 Oct 2025
EazeBio has announced a strategic partnership with the University of California, Santa Cruz (UC Santa Cruz) to advance and commercialize a groundbreaking instrument-free diagnostic platform. The collaboration will co-develop an innovative cortisol biosensor for stress and metabolic health testing, combining EazeBio’s expertise in affordable, scalable biotechnology with UC Santa Cruz’s deep research capabilities.
Finalist for ALFC 2025 Innovation Award — breakthrough science redefining healthcare with next-generation diagnostics.
India is where the story of global health equity is being rewritten.Not in boardrooms — but in research labs, maternity wards, and mobile vans reaching the last mile.This past month, as part of Eazebio’s work with AIIMS, the Indian Red Cross Society, and community health programs across Bhopal, I’ve seen what innovation truly means: listening first, then building.
Dubai is a true crossroads for innovation, investment, and global collaboration. Leaders from across industries gathered to shape the future of global healthcare and technology.
This collaboration aligns perfectly with our shared vision—leveraging cutting-edge exosomes and biomarker insights to deliver hyper-personalized, targeted therapies that go beyond traditional approaches and truly revolutionize patient care
This partnership reflects our mission to move from one-size-fits-all care to personalized, biomarker-driven solutions that improve patient outcomes. And it showcases how our platform is built to adapt across key areas—from metabolic health and post-surgical recovery to autoimmune resilience and beyond
Discover how Eazebio is pioneering next-generation diagnostics to transform women's health. Founder Reem Mahrat highlights innovative approaches addressing unmet needs, from early detection to precision therapies, empowering women with cutting-edge solutions that redefine the future of personalized healthcare and advance equity in wellness worldwide.
17 Jan 2025
A historic milestone in the realm of business excellence unfolded as the Burj CEO 2024 Awardees, representing over 40 global brands, illuminated the iconic Times Square billboard in New York. This moment etched itself not only in the annals of business recognition but also in the herts of all who bore witness to this grand tribute to achievement and leadership.
At Eazebio, we are on a mission to empower women’s health, championing groundbreaking solutions that address needs too long overlooked. But this dream—this moment—is about more than milestones. It’s about people.
EazeBio is developing next-generation biosensing technologies to make ongoing health monitoring more accessible and informative.
Consumer offerings are wellness screening tools and are not intended to diagnose or treat disease. Professional workflows are designed for clinical and laboratory environments.
Tell us a little bit about what you're looking for.
This assistant provides general information only and does not offer medical advice.